Replies to post #52763 on Biotech Values

[Biowatch]

"curbs on the abuses of Citizen's Petitions that delay opening a market"

What would it take to curb the abuses of CPs?

I thought adding personnel might help, because applications seem to languish after a few CPs (i.e., I thought the FDA ran out of interest in looking closely at an application challenged by a CP.)

[DewDiligence]

Thanks, BI. A statutory review timeline for ANDA’s would have helped in the Lovenox case however. Regards, Dew

p.s. Is it correct that only Teva and PFE's Greenstone have launched generics for Neurontin?